Executive Brings More Than 20 Years of
Pharmaceutical Experience Building Marketplace Leaders
PARAMUS, N.J., May 20, 2024 /PRNewswire/ -- Octapharma
USA, Inc. has appointed
pharmaceutical industry veteran Kelly
Hearn as Vice President of Commercial Development &
Marketing, assuming immediate leadership of the product marketing
team as the company continues to grow its presence in the U.S.
market. Octapharma USA is the
American subsidiary of Switzerland-based Octapharma, one of the
largest human protein manufacturers in the world.
During more than 20 years with Pfizer,
Kelly Hearn has demonstrated
impressive abilities to drive strategic expansion.
"Kelly Hearn brings to Octapharma
USA an entrepreneurial spirit and
a passion for developing and launching novel products to market
that improve patient health outcomes," said Octapharma USA President Flemming
Nielsen. "During more than 20 years with Pfizer, Kelly has
demonstrated impressive abilities to drive strategic expansion as
well as operational excellence and transformation. We are pleased
to welcome Kelly to our senior leadership team and look forward to
her continued success."
Hearn most recently served as Pfizer's Senior Director of
Commercial Development where she drove pipeline strategy for
Infectious and Rare Diseases. During more than two decades with
Pfizer, Hearn has led a variety of franchises both in the U.S. and
globally, and most notably played an integral role in building the
first channel and customer-centric hospital business unit for
Pfizer.
"Octapharma USA has a talented
and committed team of industry professionals focused on improving
the lives of patients with genetic and acquired blood disorders,"
said Hearn. "The company has an impressive history of developing
innovative therapies that save and enhance patient lives and I am
thrilled to be a part of the team. I am excited to bring my diverse
cross therapeutic experience to the table and look forward to
launching novel products that benefit patients while building the
company's U.S. pipeline."
About Octapharma
Headquartered in Lachen,
Switzerland, Octapharma is one of
the largest human protein manufacturers in the world, developing
and producing human proteins from human plasma and human cell
lines.
Octapharma employs nearly 12,000 employees worldwide to support
the treatment of patients in 118 countries with products across
three therapeutic areas: Immunotherapy, Hematology and Critical
Care.
Octapharma has seven R&D sites and five state-of-the-art
manufacturing facilities in Austria, France, Germany and Sweden, and operates more than 190 plasma
donation centers across Europe and
the US. Octapharma has 40 years of experience in patient care. The
company's American subsidiary, Octapharma USA, is located in Paramus, N.J. For more information, please
visit octapharmausa.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/octapharma-usa-appoints-biopharma-industry-veteran-kelly-hearn-vice-president-of-commercial-marketing--development-302149326.html
SOURCE Octapharma